title: Efficacy and safety of 120 w greenlight photoselective vaporisation of prostate in patients receiving anticoagulant drugs.
abstract: OBJECTIVE
  To evaluate the efficacy and safety of photoselective prostate vapourisation with 120 w potassium titanyl phosphate laser in benign prostate hyperplasia patients receiving oral anti-coagulant therapy.
  
  
  METHODS
  The retrospective study was conducted at Istanbul Hisar International Hosptial and comprised 63 male patients who were on anti-coagulant therapy for comorbidities and who underwent prostate vapourisation for benign prostate hyperplasia with 120 Watts potassium titanyl phosphate from November 2007 to December 2010. International Prostate Symptoms Score, Quality of Life scores, uroflowmetry pre-operatively and 3 months postoperatively were obtained. Ultrasound examination was performed for each patient to evaluate prostate and residual urine in the bladder. Plasma haemoglobin, haematocrit and International Normalised Ratio levels were also checked for patients in the pre- and post-operative period.
  
  
  RESULTS
  The age range of the patients was from 65-89 years with a mean of 72.3 +/- 8 years. The mean prostate weight was 45 +/-17 ml (range: 40-120). Mean operation time was 54 +/- 16 minutes (25-90). The removal of urinary catheter took place 1-3 days post-operatively. None of the patients required transfusion. The International Prostate Symptoms Score was reduced (23 +/- 6 vs. 14 +/- 3) at third month after the operation. Quality of Life scores were improved from 2.2 +/- 1.1 to 4.7 +/- 1.2, and maximal urine flow rate increased from 7.8 +/- 2.3 to 16 +/- 1 in the same period. Urinary obstruction due to clot retention was observed in 1 (1.58%) patient in post-operative 3 days. Urinary retention occurred in 5 (7.98%) patients after the removal of the urinary catheter. Permanent urinary retention, peroperative bleeding and post-operative incontinence were not observed.
  
  
  CONCLUSIONS
  Treatment of benign prostate hyperplasia with photoselective prostate vapourisation is effective and safe in patients receiving anti-coaguant therapy. However, patients should be monitored in early post-operative period for macroscopic haematuria and transient urinary retention.
authors.affiliation: Department of Urology, Hisar Intercontinental Hospital Istanbul, Umraniye, Turkey. drbasri@yahoo.com
authors.forename: Basri
authors.initials: B
authors.lastname: Cakiroglu
authors.affiliation: Department of Infectious Diseases, Hisar Intercontinental Hospital Istanbul, Umraniye, Turkey.
authors.forename: Ramazan
authors.initials: R
authors.lastname: Gözüküçük
authors.affiliation: Department of Urology, Maltepe University, Maltepe, Istanbul, Turkey.
authors.forename: Orhun
authors.initials: O
authors.lastname: Sinanoglu
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000008:administration & dosage*; D015897:Comorbidity; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D053685:Laser Therapy / Q000379:methods*; D008297:Male; D009929:Organ Size; D061214:Patient Safety; D011183:Postoperative Complications / Q000517:prevention & control; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000601:surgery*; D011788:Quality of Life; D012189:Retrospective Studies; D016896:Treatment Outcome; D014463:Ultrasonography; D014546:Urinary Catheterization; D014563:Urodynamics
chemical_list: D000925:Anticoagulants